Fitaro 2.4 mg/0.75 ml (SC Injection)
2.4 mg pre-filled syringe: ৳ 1,500.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Semaglutide |
| Company | Incepta pharmaceuticals ltd |
| Also available as |
Title
- Fitaro Tablet
- Semaglutide Tablet
Categories
- Diabetes Medication
- Obesity Medication
- GLP-1 Receptor Agonist
Indications
- Adjunct to diet and exercise for glycemic control in adults with type 2 diabetes mellitus
- Reduction of risk of cardiovascular events in adults with type 2 diabetes mellitus
- Adjunct to reduced calorie diet for chronic weight management in adult patients with obesity or overweight and comorbid conditions
Dosage & Administration
- Initial dose of 3 mg once daily for 30 days
- Maintenance dose of 7 mg once daily
- Additional glycemic control with dose up to 14 mg once daily
- Subcutaneous injection starting from 0.25 mg once weekly
- Subcutaneous injection site can be changed without dose adjustment
- Dosage adjustment when switching between tablet and injection
- Starting dose for obesity patients is 0.25 mg once weekly escalating to 2.4 mg
- Subcutaneous injection site for obesity patients can be changed without dose adjustment
Pharmacology
- Semaglutide is a GLP-1 analogue with 94% sequence similarity to human GLP-1
- Acts as a GLP-1 receptor agonist to reduce blood glucose in a glucose-dependent manner
- Stimulates insulin secretion and lowers glucagon secretion
- Delays gastric emptying and reduces appetite for weight and fat mass reduction
Interaction
- Delays gastric emptying impacting the rate of absorption of concomitantly administered oral medicinal products
- Should be used with caution in patients receiving oral medicinal products requiring rapid gastrointestinal absorption
Contraindications
- Hypersensitivity to the active substance or excipients
Side Effects
- Potential hypoglycemia when used with insulin or sulfonylurea
- Most frequent adverse reactions include gastrointestinal disorders, nausea, diarrhea, vomiting, abdominal pain, and constipation
- Occasional allergic reactions, injection site reaction, lipodystrophy, pruritus, and rash
Pregnancy & Lactation
- Should not be used during pregnancy
- Should be discontinued at least 2 months before planned pregnancy
- Not recommended during breastfeeding due to potential risk to the child
Precautions & Warnings
- Not to be used in type 1 diabetes mellitus or for treating diabetic ketoacidosis
- Discontinue promptly if pancreatitis is suspected
- Monitoring advised for patients with diabetic retinopathy
Use in Special Populations
- No established safety and efficacy in children and adolescents below 18 years
- No dose adjustment based on age or mild to severe renal impairment
- Not recommended for end-stage renal disease
- No dose adjustment required for hepatic impairment but caution advised
Overdose Effects
- Reported overdose up to 4 mg in a single dose and up to 4 mg in a week
- Most common reported adverse reaction is nausea
- No specific antidote for overdose
- Consider dose adjustment when adding to existing metformin, thiazolidinedione, sulfonylurea, or insulin therapy
- Guidelines for missed doses
Therapeutic Class
- GLP-1 Receptor Agonists
Storage Conditions
- Store at 2°C to 8°C in a refrigerator
- Do not freeze
- Keep out of reach of children